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Executive Summary 
 
For a nation like Bangladesh, pharmaceutical segment is a great example of overcoming 
adversity. Under the promising of 1982 medication law, the area boomed and the nation 
gradually became self-sufficient. The business sector is developing in a staggering rate. In only 
five years the extent of the business sector has become double. Pharmaceutical organizations are 
applying their best push to acquire piece of the overall industry and be a part of the development. 
Sanofi Bangladesh Limited is no exception. Along with other strategies like bringing up their 
own research product to Bangladesh market, they are additionally attempting to win more 
noteworthy offer of the generic market. Launching CNS product was a choice in compatibility 
to their development arrangement. This report was set up as an internship report to satisfy the 
system completion prerequisite of the BBA Program at BRAC University and the preparation 
work was done in Sanofi Bangladesh Limited. In the preparation program, firsthand experience 
was picked up with respect to pharmaceutical item dispatch by working in the CNS portfolio 
launching project. The expectation of the internship training was to acquire some certifiable 
experience by working in a viable situation. Pharmaceutical marketing is a sensitive job; product 
launching is considerably more than that. The inter-departmental nature of the work makes it to 
a great degree of communication. The product manager needs to oversee such a large number of 
partners that he must be exceptionally cautious about keeping up the equal balance. Starting from 
the market analysis and profit-loss investigation, careful subjective and target basic leadership 
capacities are required. Meeting the due date is constantly critical however it turns out to be all 
the more so if there should arise an occurrence of product launching. Product launching is 
additionally a critical experience for a manager because it requires collaboration with each of 
the department of a pharmaceutical organization. This is assumed that the most ideal method for 
getting an inside and out of the pharmaceutical marketing sector. Being included in the product 
launching team at Sanofi Bangladesh Limited was an outstanding experience.   
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1 Introduction 
1.1 Background 
 
Pharmaceutical area is a standout among the most flourishing sectors in Bangladesh. The 1982 
drug ordinance coordinated the entire business in such a good course, to the point that in the late 
years Bangladesh is practically independent in delivering drug. The neighborhood local drug 
producers thrived in the most recent three decades, crossing the multinational pharmaceutical 
organizations from leading position in the business sector. The multinational organizations are 
battling back with a superior quality suggestion and keeping on offering new items. Despite the 
fact that the oppositions are ruling, the shoppers are being profited by the tough competition 
among the local and multinational organizations. 
 
Being one of the main multinational pharmaceutical organizations working in Bangladesh, 
Sanofi Bangladesh Limited is applying its best push to wind up one of the main 5 organizations 
in the nation. The company is making new launching of originator products and also generic 
products to stay in line with the market dynamics. This report is the study of an upcoming product 
of Sanofi Bangladesh Limited. The new launch "Leveron" has been subjected to study to keep 
an eye on the starting strategy of a pharmaceutical product. 
 
1.2 Origin of the report 
 
This report was made as an internship report to meet the project completion necessity of the BBA 
Program at BRAC University. The report was finished on the proposed topic "Launching of 
Leveron: Report on a new anti-Epileptic product launching of Sanofi". The expectation was to 
increase some true experience by working in a reasonable domain in a relative field. The 
internship supervisor was Dr. Imtiaz Ahmed Firoz, Head of Business Unit, CNS, Sanofi 
Bangladesh Limited and the faculty advisor was Mrs. Afsana Akhtar, Assistant Professor, BRAC 
Business School, BRAC University. 
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1.3 Objective of the report 
 
The objective of this report was to find out the followings:  
 The way new product feasibility study is done in a pharmaceutical company 
 Product launch plan formulation 
 Execution of product launching  
 Personal findings and analysis on overall activities   
 Required recommendations 
The result of the intensive study done at the time of internship has been spoken to and united in 
this report to satisfy the goal of this report. 
 
1.4 Scope of the report 
 
This report studies a single product: ‘Leveron’ of the upcoming CNS department of Sanofi 
Bangladesh Limited. The internship period of the report is from May 3,2016 to July 31, 2016. 
 
1.5 Methodology 
 
The report has been made on the premise of essential information gathered from the real life 
activity and secondary data gathered from productions and web. The gathered information was 
analyzed properly. The information analysis process supported by the organization has been 
utilized to analyze information for the report. 
 
1.6 Limitations 
 
In some instances, actual numerical figures were not presented in the report due to confidentiality 
issue. Another limitation is the scientific description provided by the internal doctors of the 
company which may or may not be accurate. Due to a different expertise area, I could not verify 
by myself but taken other doctors references on that case.  
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2 Overview 
2.1 Industry Overview 
 
Pharmaceutical industry is mechanically the most amassing manufacturing industry in 
Bangladesh and the third greatest industry in terms of government’s revenue. The business 
contributes around 1% of the total Gross Domestic Product. There are around 250 authorized 
pharmaceutical makers in the nation, however, as of now somewhat more than 100 organizations 
are in operation. It is exceedingly focused as main 20 organizations produce 85% of the income. 
As per IMS, a US-based statistical surveying firm, the retail advertise size is evaluated to be 
more than BDT 84 billion as on 2015. 
 
Directorate of Drug Administration and Pharmacy Council of Bangladesh are controlling the 
pharmacy sector in Bangladesh. Bangladesh Pharmaceutical Society is partnered with worldwide 
associations International Pharmaceutical Federation and Commonwealth Pharmaceutical 
Association. 
 
Bangladesh pharmaceutical companies concentrate principally on branded generic formulations, 
generally utilizing imported APIs (Active Pharmaceuticals Ingredient). Around 85% of the 
medicines sold in Bangladesh are generics and 15% are protected drugs - the structure contrasts 
essentially from the worldwide business sector. Marked generic medicines cover around 25% by 
and large of overall pharmaceuticals sales. Compare to the growing markets like China, India 
and Latin America, marked generic drugs may play a huge role in sales within 12 years. 
Bangladesh makes around 450 molecule medicines for 5,300 enlisted brands which have 8,300 
distinct types of measurements and qualities. 
 
Local medicine makers hold up to 97% of the medicine sales in the local market while whatever 
remains of the 3% are transported in. This is a completed turnaround over from two/three decades 
back when imports used to overpower the market place. The imported drugs include essential 
lifesaving drugs and other high quality drugs. The ratio will further rise due to the local 
production players. As communicated some time recently, the degree of the retail publicizes 
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accomplished BDT 84.0 billion as on 2015 checking IMS report. The report further expressed 
that, retail deals in the local business sector accomplished 23.6% development in 2015 after 
23.8% and 16.8% development in 2014 and 2013 individually. High development in the most 
recent three years (78.8% combined and 21.4% CAGR) implied that the Bangladesh 
Pharmaceutical business sector multiplied in a little more than four years. The retail market 
additionally crossed USD 1.0 billion in size in 2015. It is one of the speediest creating sections 
in the country with a yearly typical improvement rate of 17.2% all through the latest five years 
and 13.1% over the span of the latest decade.  
 
In any case, considering that IMS excludes rural part in their research, the genuine size of the 
business will move fairly (5%-10%). It is assumed that the retail marketing addresses 90% of 
the total business in such manner the total business segment size (counting the rural market) is 
depended upon to be over BDT 90.0 billion at present. Government burning through degree is 
much lower than that in various districts - it is one possible reach where future advancement may 
begin from. Since the base is still low, we expect the late improvement in the area retail market 
to continue in the present decade. According to my level of understanding, some other factors 
that will also boost the industry growth include: 
 
 Mass people are becoming more health conscious 
 Increase amount of exported pharmaceutical products 
 Increase in level of treatment provided in the hospitals with improved diagnostic equipment 
 Increase in number of modern hospitals 
 Growing the income level of the mass people 
 
If these steps are implied, we can be hopeful of some massive economic growth of pharmaceuticals 
industry in our county. 
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2.2 Sanofi Worldwide 
 
Sanofi, a main worldwide pharmaceutical organization, finds, creates and circulates helpful 
arrangements. Sanofi is the one of world's driving Pharmaceutical organizations and the biggest 
in Europe. Present in more than 100 nations, with around 11,000 researchers, Sanofi has around 
100,000 representatives attempting to enhance wellbeing and prosperity. The Global central 
command is in Paris, France 
Sanofi focuses its activities on 7 major therapeutic areas:  
 Cardiovascular  
 Thrombosis  
 Oncology  
 Central Nervous System (CNS) 
 Metabolic Disorders  
 Internal Medicine  
 Vaccines  
 
With more than 25 research centers on three continents, Sanofi facilitates its Research and 
Development on an overall premise. The Sanofi yearly R&D spending plan surpasses 4 billion 
Euros and positions among the three biggest spending plans of worldwide pharmaceutical 
industry. Sanofi currently possesses one of the richest and most innovative portfolios in the 
industry with more than 100 molecules and vaccines in development, half of which are in 
advanced stages. The group devotes its research in finding innovative, effective and safe 
medicines that give new and better solution for patients.  
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2.3 Sanofi worldwide: Timeline 
 
Sanofi is the beneficiary to a long history that incorporates a portion of the major scientific 
advances of the 19th and 20th century. In 1718, Laboratories Midy was established by a group of 
drug specialists. In 1980, the ClinMidy gathering was gained by Sanofi.  
 
Laboratories Dausse was established in 1834 and is Laboratories Robert and Carriere in 1901. 
They converged to make Synthelabo in 1970. In 1860 the drug specialist Etienne Poulenc made 
Wittmannet Poulenc Jeune. What's more, in 1910 the ball was in Rorer's court. The two 
organizations in the long run converged to frame Rhône-Poulenc Rorer in 1990.  
 
In 1863, a gathering of scientific experts, sales representatives and laborers set out on the 
assembling of colors in a little production line toward the west of the town of Hoechst in 
Germany. This was the root of the organization Hoechst, which converged with Roussel 
(established in 1911) to frame Hoechst Marion Roussel. In 1887, Marcel Merieux, an understudy 
of Louis Pasteur, establishes the Merieux Biological Institute which, in 2004 got to be Sanofi 
Pasteur, the Sanofi's vaccine division.  
 
The two young groups Sanofi and Synthelabo converged in May 1999 to make a big new 
pharmaceutical company. Sanofi dated back to 1973 and Synthelabo to 1970. In December 1999, 
Rhone-Poulenc and Hoechst Marion Roussel formalized their merger with the making of the 
Franco-German gathering Aventis, one of the world's biggest pharmaceutical organizations.  
 
In August 2004, Sanofi-Synthelabo procured Aventis. The takeover was concluded on December 
31 of that year, bringing forth Sanofi-Aventis.  
 
On May 6, 2011, Sanofi-Aventis simplified its name to Sanofi.  
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2.4 Company Overview: Sanofi Bangladesh Ltd. 
 
I consider myself fortunate enough to work with a company like Sanofi Bangladesh Limited. 
Sanofi is one of the world's driving pharmaceutical organizations which are devoted to the 
innovation, advancement, creation and distribution of meds and vaccines for all throughout the 
world. Sanofi is the biggest worldwide pharmaceutical organization in Bangladesh with a 
dedicated group of more than 1200 workers.  
 
Sanofi Bangladesh Limited is the face of three legitimate substances Aventis Limited, Fisons 
(Bangladesh) Limited and Hoechst Marion Roussel Limited. The legal integration process has 
taken few years after the global merger between Sanofi - Synthalebo and Aventis in 15 
September 2004 and finally the existing three legal entities have amalgamated as Sanofi-Aventis 
Bangladesh Limited on December 11, 2007. The head office of Sanofi Bangladesh Limited is 
now in Segun Bagicha, Dhaka - 1000. 
 
Sanofi Bangladesh Limited has distinctive pharmaceutical products includes prescription 
medicines, vaccines and nonprescription medicines. Our specialist endorsed meds run across 
over different zones, for instance, anti-bacterial, respiratory, psychiatry, oncology, 
gastrointestinal, cardiovascular and distinctive contaminations. The association is the business 
segment pioneer in most of the supportive classes in which it works. They offer a scope of 
vaccines for the avoidance of hepatitis A, hepatitis B, obtrusive sickness brought about by H, 
flu, chickenpox, diphtheria, pertussis, lockjaw and others.  
 
Locally, Sanofi incorporates Sanofi Pasteur, a world pioneer in antibodies. In Bangladesh, 
antibodies like TetavaxTM, VerorabTM, Euvax BTM, AvaximTM, ACT-HIBTM, 
TyphimViTMetc are incorporated into the portfolio. 
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3 Responsibilities during Internship 
 
The internship program was started on May 3, 2016. The internship was to last for three (3) 
months and as a result the internship period came to an end on July 31, 2016.  
 
Sanofi Bangladesh Limited was planning to launch a new product portfolio, consisting of 
psychiatric products. The author of this report was assigned to the CNS new launch project and 
this report is based on the experience obtained there. The major brand of the CNS portfolio, 
‘Leveron’ was decided to be the brand of interest of this report. 
 
 
3.1 Major Job Responsibilities (but not limited to): 
 
 Understand and find new market opportunities 
 Know relevant top KOLs across country and develop strong association with them 
 Develop promo materials to establish brands as per policy and measure effectiveness of 
the materials 
 Organize and conduct planned seminars for the new product 
 Organize sales training for new product and updated information 
 Analyze data and share with respective field colleagues 
 Monitor Rx Survey in 4P and Business Unit Online Platform 
 Managing congress for doctors as per their potentialities 
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4 Product Overview 
4.1 Product 
 
One of the upcoming products of Sanofi Bangladesh Ltd.: ‘Leveron’, is the subject of interest of 
this report.  
 
Figure 1: Brand logo 
 
The product is scheduled to be launched on June, 2016. Details of the brand are given bellow:  
 
Criteria  Details  
Therapeutic class    LEVETIRACETAM 
IMS Code  N03A 
Original company / brand  UCB- Keppra 
Product type  ANTI-EPILEPTICS 
Indications  
Treating partial-onset, myoclonic, or generalized 
tonic-clonic seizures in patients with epilepsy 
Dosage, strength & pack sizes  
250mg Tab (20’s); 500mg Tab (10’s); 500mg 50 ml 
Solution (1’s); 500mg 5 ml Injection (6’s) 
No. of Clobetasol brands  Six (6)  
Market size  122 M BDT (76% CAGR growth ’13-‘16)  
 
Table 1: Product details 
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4.2 Competitors’ Products 
 
There are currently 5 other Levetiracetam brand present in the market, which are the direct 
competitors of the brand ‘Leveron’. The major competitors are as follows:  
 
Brand  
Name  
Generic  
Name  
Company  Presentation  
 
Pack Size  
 
ERATA 
Levetiracetam 
Sandoz 
Tablet 250mg (20’s) 
Tablet 500mg (10’s) 
CITAZAR 
Levetiracetam 
        ACI 
Tablet 250mg (20’s) 
Tablet 500mg (10’s) 
IRACET 
Levetiracetam 
Square  
Tablet 250mg (20’s) 
Tablet 500mg (10’s) 
   Solution 500mg 50 ml (1’s) 
   Injection 500mg 5 ml (6’s) 
 
Table 2: Major competitors  
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5 Launch Planning 
5.1 Launch Planning at Sanofi 
The initiation point of product launching at Sanofi is the NPC (New Product Committee). This 
committee is headed by the Managing director and consists of the following members: Director 
Business Operations, Director Specialty Business, Director Business Excellence, Director 
Supply Chain, and Director Industrial Affairs.  
This committee continuously analyzes the market information and explores the potential of new 
products. Any proposal of new launch is initiated by a NPC member in its meeting. If any 
molecules seem significantly potential in the primary analysis, then it is preceded for feasibility 
analysis.  
 
5.2 Market analysis 
 
Based on the available IMS data, market analysis has been done and projection has been done 
for ‘Leveron’ up to year 2015:  
Value K BDT  2013 2014 2015 2016 
LEVETIRACETAM (IMS Code: 
N05A)  22,287 39,058 77,472 121,946 
TC Growth 76%   18% 43% 98% 57% 
      
Competitors            
ERATA Sales  16,991 27,420 42,322 57,859 
Sandoz M.S 76% 70% 55% 47% 
  Growth% 40% 61% 54% 37% 
IRACET Sales  719 5,443 21,728 39,851 
Square M.S 3% 14% 28% 33% 
  Growth% 205% 657% 299% 83% 
CITAZAR Sales  3,058 3,715 6,463 9,496 
ACI M.S 14% 10% 8% 8% 
  Growth% 15% 21% 74% 47% 
Sanofi Product           
LEVERON Sales  0 0 0 6,474 
Sanofi  M.S NA NA NA 5% 
  Growth% NA NA NA NA 
 
Table 3: Market Analysis 
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This is a primary analysis and the forecast will be adjusted after launching in accordance with 
market dynamics, product performance and sales force size.  
 
5.3 Go-No Go decision 
 
The market analysis of the molecule Levetiracetam demonstrated that it has a noteworthy 
business sector volume in Bangladesh and has a solid development prospect. In light of the 
business sector investigation it is discovered that the Levetiracetam brand will contribute 
fruitfully to the business. This elaborate analysis enabled the NPC to decide ‘GO’ for a 
Levetiracetambrand and the launching responsibility was handed over to the marketing team 
CNS. The brand name was set to be ‘Leveron’.  
 
5.4 Pricing and Forecast 
 
Evaluation of pricing of a product is done considering two elements: Gross Profit and contender's 
cost. Considering the competitors value, the cost of a recently launched product is set in a manner 
that it would contribute no less than 78% gross benefit. Altogether higher or lower cost than the 
competitors is extraordinary in pharmaceutical industry. Just in the event of some premium 
product, cost is set at a premium rate. Since "Leveron" is neither a premium item nor an 
originator's item, the customary valuing approach was used to set the brand's cost. The two info 
elements: COGS and competitors cost was important deciding parameters here. The cost while 
set equivalent to the competitors cost appeared to produce huge gross benefit. Through 
calculation of diversified cost and returning gross benefit, it was chose that the price will not be 
varied from the contenders. The at last chose cost of "Leveron" is as per following: 
Brand Name  Presentation  MRP/Pack  TP/Pack  
Leveron  
250mg Tablet (30’s) 482 361 
500mg  Tablet (20’s) 602 451 
 
Table 4: Pricing 
 
  
20 
 
While fixing the price, a primary forecast has been done by the marketing department for the 
brand:  
 
 2016 2017 2018 2019 2020 
Brand 
Name  Vol  Val  Vol  Val  Vol  Val  Vol  Val  Vol  Val  
Leveron  51 9111 97 13911 136  19475 176  25318  221 31648  
 * volume in K  
 Unit, ** value in K BDT   
  
 
Table 5: Five-year forecast  
 
5.5 Budget allocation 
 
The initial step of allotting cost spending plan is to decide the business spending plan of a 
product. Every year a business spending plan is set to be accomplished by the specialty unit. This 
business spending goes about as the objective to be accomplished and set by the product 
manager. This budget plan is then looked into and concluded after feasibility evaluation and the 
business operations head affirms the last sales budget. Depending on the targeted sales budget, 
AnP budget (Advertising and Promotion budget) is allotted for a product. The brand ‘Leveron’ 
is not a budgeted product in 2016, meaning it does not have any targeted sales budget which is 
to be achieved in 2017. So the expense budget cannot be allocated based on sales budget. Since 
it’s a new launch, special approval expense budget has been allocated for the brand to start 
promotion in 2016. Structure year 2017 and onward, "Leveron" will be a planned item (i.e. will 
have a business spending plan, which will must be accomplished by the specialty unit) and will 
have cost spending plan distributed on the premise of that business spending plan. 
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6 Pre-launch Activities 
 
6.1 Marketing Strategy 
 
A marketing system structure was created for the item 'Leveron'. Recorded beneath are the 
progressions of the marketing methodology system: 
 
Step 1: Background studies 
Through background studies were done to access the necessity of Neurological product in the 
current market. 
 
Step 2: Situation Analysis (SWOT)  
SWOT investigation distinguishes the opportunities and difficulties in the Neurological market. 
 
Step 3: Target Audiences  
Target gathering of people is distinguished to solidify the customer base and build up the best 
possible showcasing strategies. Here, Neuromedicine and Medicine doctors are our first target. 
 
Step 4: Marketing Goals  
Based on the background analysis, situation analysis and target audience analysis, marketing 
goals were set.  
 
Step 5: STP (Segmentation-Targeting-Positioning)  
Segmentation and targeting was done with through data analysis. Proper positioning was done 
keeping the target market and consumers in mind.  
 
Step 6: Development of promotional plan  
After executing STP exercise, a through promotional plan was developed to convey the 
positioning statement to the mind of the targeted customers.  
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6.2 Analyzing Customer Base 
 
Pharmaceutical products are different from other products (like FMCG products) in several 
ways. Among different angles, customer base is one of the major separating components. In 
pharmaceutical industry the purchasers of the items are not the target customers of the 
pharmaceutical organizations. When diagnosing a disease, the Physicians recommend the 
medication to the patients. In Bangladesh, doctors are allowed to recommend any brand of a drug 
molecule fitting to the patient's neurotic condition. On the off chance that a patient is determined 
to have partial epilepsy, a doctor can endorse any brand to that specific patient, the length of he 
feels that particle is the proper pharmaceutical for the patient. The patient then goes to the 
scientist shop/drug store with the remedy and the drug specialist/scientific expert fills the 
solution with the brand of the medication endorsed by the doctor. From this situation it is clear 
that the doctor specifically impacts the offers of the brand yet the real buy is finished by the 
patient. In the vast majority of the cases the patient or the drug specialist does not change the 
brand of the prescription while the genuine deal happens. Special case is watched just in the 
event of some OTC (over the counter) tranquilizes, brand substitution may happen there. 
 
This element must be remembered while doing the customer base investigation for any 
pharmaceutical brand. The brand of enthusiasm of this report, "Leveron" is a physician 
recommended solution. That is the reason; examining the prescriber base of the molecule of 
"Leveron" was considered as the suitable method for getting an unmistakable thought of the 
Brands customer base.   
 
To examine the customer base, prescription information acquired from a pharmaceutical 
statistical surveying firm: 4P marketing consultancy was utilized. 4P gives week by week 
medicine study information to its clients. Sanofi is a customer of 4P advertising consultancy and 
gets prescription information from them on an occasional premise. The statistical surveying wing 
of the business excellence department of Sanofi dissects the information as per the need of the 
business units and scatters the report to the entire Specialty Care unit. 
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The CNS project additionally gets the prescription overview information on every single existing 
brand of Levetiracetamin a week after week premise. This database was used to create target 
customer investigation report. A one-year time line (April 2015 to March 2016) was been the 
time allotment. The report comprised of around 16500 instances of prescription generation of 
the applicable brands. From that point, 4500 interesting specialists were distinguished and most 
potential 1680 specialists were masterminded in a pool to be focused on. This essential report 
was shared to the current sales line of the Sanofi Specialty Care unit to confirm the subtle 
elements and location of the targeted doctors. The District Managers of Sales were permitted to 
include or subtract name and points of interest of the potential doctors. Subsequent to getting the 
updated list from the District Managers of Sales, segmented information base was merged to 
conclude the target doctors.  
 
6.3 Segmentation 
 
Levetiracetam (the active pharmaceutical ingredient of the brand ‘Leveron’) is the most potential 
prescribers of the molecule were analyzed for doctor specialty distribution. The information was 
broken down to discover the quantity of specialists in every claim to fame portion for the 1680 
benchmark prescribers. From among them the most and the minimum potential fragments were 
distinguished. It was observed that the Neuromedicine and General Medicine claim to fame are 
the most potential fragments and Surgery and Gynae are the least potential sections.  
 
6.4 Targeting 
 
From among the segmented sectors, the most potential ones were focused on and the slightest 
possibilities were prohibited. To support the 1680 baseline prescribers, more specialists for the 
focused on sections were included from the database. Majors for the targeted segments were 
added from the database. The targeting scheme makes the orientation more engaged and it will 
make it less demanding to position the items in the focused on portions. The focus on specialists 
fragments of "Leveron" are the General Medicine and Neuromedicine specialists. 
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6.5 Positioning 
 
Positioning implies the discernment work in the brain of the customer about the product. For the 
item 'Leveron', the undertaking of positioning was a technical stuff to do. Since there is an 
extremely settled brand: Erata, is overwhelming the business sector, it was important to give a 
basic and exact message to the focused on client base to create discernment about the brand. The 
particular disease class was focused on and "Leveron" was positioned as the viable and safe 
alternative to oversee partial epilepsy.  
 
6.6 Planning and Developing Promotional Material 
Creating and planning promotional material is an extremely basic stride in pharmaceutical 
advertising. If there should be an occurrence of a starting item, the significance is further 
extended to the starting special materials should make the buzz among the target customer, who 
are habituated to recommend different brands. For the upcoming brand ‘Leveron’, printed 
promotional materials have been developed for the starting month. Printed promotional materials 
include literature, drop card, slip pad, leaflet and scientific journal article.  
 
Promotional 
Description material for 
‘Leveron’ 
Literature 
Contains fundamental experimental data with respect to the 
disease, logical study showing the medication's potential and 
safety and security profile, pack info, recommending 
information. Contains brand logo. 
Single card 
Contains all the information contained in an item writing in a 
brief structure. Contains brand logo as well. 
Slip pad 
Endorsing pad containing extremely short data. Contains 
brand logo. 
Leaflet 
Contains overall information and rule to the disease 
management. May contain brand logo. 
Scientific journal Article concentrating on the disease. 
 
Table 6: Promotional materials 
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All promotional material needs to experience two distinctive investigation forms. Inside the 
Medical and regulatory affairs department of Sanofi gets to the reason and propriety of the 
special material. At that point everyone must be affirmed by the national regulatory body: The 
Drug Administration.  
All the promotional materials are made for ‘Leveron’ has undergone this process and all of them 
are finally granted to be circulated among our target doctors.  
 
6.7 Field Force Deployment 
 
Man power arranging was done as per geographic distribution of the target clients. The sales line 
which will execute the sales movement of the brand "Leveron" is the CNS sales line. This will 
be the sales line committed to all CNS brands among which "Leveron" is the leader brand. 
A table has been given below for better understanding: 
 
Region  Number of 
target doctors  
 
Number of 
sales reps  
 
Dhaka I  300 5 
Dhaka II  300 5 
Chittagong  180 3 
Comilla  180 3 
Sylhet  300 5 
Bogra  240 4 
Khulna  180 3 
Total  1680 28 
 
Table 7: Field Force Deployment 
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In 2016, the CNS sales line agents will be dealing with Levaron along with other brands of this 
business unit. This sales line is divided in 7 regions nationwide, having a District manager (DM) 
or a Regional Sales Manager (RSM) for every region. 
 
The newly appointed sales reps will be reporting to the respective regional sales manager of his 
respective region. The CNS business unit will not directly supervise the sales activity. The 
number of target doctors is not equally distributed among all the regions, in highly potential 
regions like Dhaka-1 and Dhaka-2 the number of target doctors is more than the other regions.  
 
One sales person will be appointed to cover 60 target doctors. As per this policy, Dhaka-I, Dhaka-
II and Sylhet will have 5 reps each and all other regions will have three reps to cover the target 
doctors. Additionally, Bogra region will have four reps. In total, 28 reps will handle the CNS 
sales line in the launching year (2016). Potential deals reps among the current locales are being 
met to be conveyed to the CNS sales line. The opening made by the exchange of reps from the 
current sales line will be topped off by newcomers. Since, CNS sales line will advance a radical 
new portfolio, the accomplished deals reps are being exchanged from different deals line as 
opposed to naming newcomers. 
 
6.8 Developing Training Material 
 
Before launching of any new item, an essential step is to prepare the sales team appropriately. 
By chance if another item is like any current item (i.e. of the same therapeutic class) it is less 
hectic to execute the preparation assignment since the reps are familiar with the information of 
therapeutic class and related ailments. Since there are many existing antibiotic items are actively 
promoted, the training process of a newly launched antibiotic will be much more convenient. Be 
that as it may, the task gets to be harder if a pharmaceutical item is of a novel therapeutic class. 
Since, Sanofi is currently not doing active promotion of any neurological products, sales reps are 
not acquainted with this type of products. This makes the training process is of much importance 
for the CNS sales line.  
 
  
27 
 
There are two standard training materials which are developed for each and every launching 
product. These are as follows:  
 Training manual and presentation  
 Brand book  
 
Training manual:  
 
The training material is a complete rule to the sales agent. This manual covers a huge number of 
topics, running from fundamental physiological facts to market specific elements. The manual 
typically comprises of two sections: the disease part and the product part. Based on the reference 
material a presentation is made which is utilized as a part of the instructional courses of the sales 
reps.  
 
Brand book:  
 
Another vital training material is the brand book. The brand book depends on the printed 
promotional materials. A brand book has been created for the starting item 'Leveron'. In the 
printed promotional material, the experimental data is exhibited in an easy way with helping 
visual. In the brand book substance of the printed promotional materials are expounded. The 
sales agents make call to the specialists physically to promote the item and the brand books 
contains guideline covering each part of a call. It educates how to approach the specialist, how 
to detail the printed promotional material and how to draw in the specialist. Probable complaints 
by the specialists are additionally examined in the brand book.  
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7 Launching 
 
At the point when cost is endorsed by the drug administration, plant is prepared to produce and 
all the promotional material is prepared then the real Launching operation is started. For the 
brand 'Leveron', it will be started in the third week of June 2016. There are a few stages in the 
starting operation. These are discussed below: 
 
7.1 Training program for the sales forces 
 
For each sale, month to month meeting is held in the start of every month. For the CNS deals 
line, the main such meeting will be hung on the start of the starting month (tentative date: June 
19, 2016). In this meeting the preparation of the business powers will be led. In light of the 
instructions developed, the marketing department will give preparing on the accompanying 
modules: 
- Product overview  
- Market overview  
- Scientific details of the product  
- Marketing and sales techniques 
In collaboration with the marketing department, the ‘Sales force training department’ will 
provide training on sales techniques. 
 
7.2 Pipeline filling 
 
After the manufacturing plant delivers the first batch of the item, the product manager of the 
marketing division settles the assignment of the product to the 18 warehouses of Sanofi all 
around the nation. The portion depends on the geographic distribution of the target customer. 
The business delegates then approach the scientific expert shops/drug stores with a launching 
letter and educate them about the launch of the product. At that point, according to the demand 
from the physicists/drug specialists, supply is started. For Leveron, this pipeline filling activity 
arrangement has been finalized. 
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7.3 Initial Communication with target customers 
 
Immediately just after executing the pipeline filling task, the main experience with the target 
customers (the target doctors) takes place. A useful letter is set up to be conveyed to the doctors 
by the sales reps in individual. The doctors' letter contains the fundamental data about the starting 
product, the diseases in which it is successful and some different briefings about the item. For 
Leveron, the specialists' letter has been arranged and is booked to be circulated to every single 
one of the 1680 target doctors. 
In this first meeting the sales representatives will inform the target doctors about the very 
essential information about the product: its molecule, indication, relevant patients and price. 
They will assure the target doctors that the product has been made available in the chemist 
shops/pharmacies and the product will be available to the patients if it’s prescribed. 
 
7.4 Starting the promotional activity 
 
In this stage, the promotional activities are started. Pipeline filling and initial communication 
with the target customers will create the ground to formally initiate the promotional activity. The 
promotional activity of ‘Leveron’, will be done following a monthly plan, which is called cycle 
plan. The cycle plan clearly defines which promotional activity should be carried out when in a 
specific month. The cycle plan for the launching month of ‘Leveron’ has already been developed. 
To execute the cycle plan, target doctors are arranged in three categories according to their 
prescribing potential:  
 
Category ‘A’ doctors: Most potential  
Category ‘B’ doctors: Medium potential  
Category ‘C’ doctors: Average potential  
 
It has been planned that the category ‘A’ doctors will be visited by the sales representatives eight 
times a month (twice a week). Category ‘B’ and Category ‘C’ doctors will be visited six and four 
times a month respectively. Each visit will deliver at-least a printed promotional material or a 
gift. Each visit will generate a strike to the mind of the doctor about the brand. There is also a 
  
30 
 
rough outline of cycle plan developed for the remaining months of 2016. It is expected that the 
promotional activity of the launching month will create awareness of the brand among the 
doctors and analyzing the result the promotional plan of the coming months will be adjusted. 
 
8 Post-launching 
 
After launching the product, the major activities planned to be performed after launching are 
discussed here. First of all, the performance is monitored in a monthly basis so that the growth 
of the product can be triggered. After that, the profit loss scenario is reviewed by the specialists. 
Then the sales force do right sizing. At last, the allocated budget is reviewed according to product 
performance. So the formalities do not really end after launching the product but continues in 
further stages 
 
9 Findings  
 
I am a student from business background. So by nature I did not have any involvement with the 
pharmaceutical business anyhow. This was thus really an interesting opportunity for me to work 
with Sanofi. I learnt some different tools and mechanisms here what I could not possibly get in 
any other industry. So my findings list is a bit long. There are some useful findings I have found 
during my internship in Sanofi. I would like to share those here.  
 
a. Marketing Strategy: The marketing strategy in a product based company is apparently 
different from a pharmaceuticals company. They do not create advertisements in 
television or on social media but they take some different initiatives to let their customers 
know about their new products. 
 
b. Industry knowledge: I was open to a new source of information from a different type of 
industry where probably most of things I learnt in my graduation, was different. I was 
exposed to diversified knowledge of the company. 
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c. Different Marketing Promotional Materials: The different promotional materials used 
by a pharmaceutical company, specifically Sanofi, are literature, single card, slip pad, 
leaflet, scientific journals and such. The logo is attached to maximum of the Medias so 
that people easily can relate with the brand. 
 
d. Relationship Marketing: Pharmaceuticals companies are surviving upon relationship 
marketing. The personal and business relationships maintained with the doctors are the 
major type of marketing strategy they are using. Sometimes this way seems somewhat 
exaggerating but lack of proper law makes it easier to practice.  
 
10  Analysis 
 
This part is more in depth knowledge I gathered during the internship period. 
 
a. First of all, according to my perspective, the aftermath of producing a product and 
launching it is very time consuming for a pharmaceutical company. After producing any 
medicine, a test named ‘Shelf Life’ is executed which means it will be kept for shelf for 
long 6 months to check its quality. After every three months, the quality is checked. 
Though Sanofi maintains this step but most of the local companies not really follow these 
process which leads to further problem of the produced product. 
 
b. When a new product will be launched, pharmaceutical company’s especially 
multinational companies need government and many other authorized approvals. These 
processes are slow as well as time consuming in our country. And thus it happens to be 
a major hindrance to the pharmaceuticals companies.  
 
c. Next, a pharmaceutical company will obviously need raw material to produce and 
generate their products. In Bangladesh, the main ingredients are available but there are 
other ingredients which are not available here and have to be fetched from abroad. This 
makes the production slower. 
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d. Another minor issue for Sanofi is the point at which another medication is being 
produced; drug stores decline to take the new medication until the specialists generate 
prescriptions. Then again, specialists likewise get to be hesitant to recommend the new 
medication until it is available in the store. So it turns out to be practically difficult to 
propel them two at the same time. 
 
11 Recommendations 
 
Working with Sanofi, I have got to have some personal insights. I have to admire that the way 
they work is near to perfect but still there are some hindrances that comes in their operations. I 
have found out there are some approaches to ignore the obstacles that come on the way of 
launching a product. Completing a 3 month long Internship program at Sanofi and watching their 
starting exercises, my suggestions for Sanofi would be: 
 
 Being the largest pharmaceuticals company, there is still lack of awareness in common 
people in our country who did not even hear the name of Sanofi. May be they do not need 
public popularity but they should be exposed to a minimum level. In my perspective, 
Sanofi should come up with a marketing strategy targeting the common people of our 
country.  
 
 The launch of different products of Sanofi sometimes gets delayed affected by  
maintaining too many regulations. So they ought to make their product launching 
program very earlier so that they do get sufficient time to complete the formalities. 
 
 As I have already stated above, the company offers gifts to different doctors for free as 
marketing strategy but I think the government should make proper rules in giving gift 
materials to the specialists from the pharmaceutical organizations. There will be some 
sure standards about what sorts of gifts are permitted and what are not took into account 
pharmaceutical organizations. 
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12 Conclusion 
 
Bangladesh pharmaceutical business division is spanning in an amazing rate. In just five years 
(from 2012 to 2016) the measure of the business division has become double. Competition in 
the market is huge but the potentiality of this market is still there and growing day by day. Sanofi 
Bangladesh Limited is no exclusion. Along with other techniques like bringing up their own 
research product to Bangladesh pharma market, they are also trying to win greater share of the 
generic market. Launching the new product in CNS portfolio is a great step in getting a more 
conspicuous foothold in the market of generic.  
 
Pharmaceutical marketing is a significant job in this market. When it comes to launch a new 
product, it’s even more challenging. The interdepartmental way of the occupations makes the 
work more connecting. The head of the CNS portfolio needs to oversee such a large number of 
partners that he must be exceptionally watchful about keeping up the balance. Meeting the due 
date is constantly vital for launching new item. A proficient communication way must be kept 
up between the linkage partners (supply chain & production) to the forward linkage partners 
(distribution & sales). Additionally, maintaining stakeholders is also a promising task to do. 
 
Experiencing such kind of job, I can boldly claim launching a new product in pharmaceutical 
company specially in a multinational company is a prominent job to complete. For me this is the 
most ideal method for getting an inside and out of the pharmaceutical marketing job. Being a 
part of the launching team and worked with different departments at Sanofi Bangladesh Limited 
was an outstanding experience along with earning huge knowledge about pharma industry. 
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